224 related articles for article (PubMed ID: 26206718)
21. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.
Kim J; Eltoum IE; Roh M; Wang J; Abdulkadir SA
PLoS Genet; 2009 Jul; 5(7):e1000542. PubMed ID: 19578399
[TBL] [Abstract][Full Text] [Related]
22. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
[TBL] [Abstract][Full Text] [Related]
23. Expression of PTEN in malignant and non-malignant human prostate tissues: comparison with p27 protein expression.
Fenic I; Franke F; Failing K; Steger K; Woenckhaus J
J Pathol; 2004 May; 203(1):559-66. PubMed ID: 15095479
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.
Wang S; Gao J; Lei Q; Rozengurt N; Pritchard C; Jiao J; Thomas GV; Li G; Roy-Burman P; Nelson PS; Liu X; Wu H
Cancer Cell; 2003 Sep; 4(3):209-21. PubMed ID: 14522255
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
Wu Z; He B; He J; Mao X
Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044
[TBL] [Abstract][Full Text] [Related]
26. An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.
Mirantes C; Eritja N; Dosil MA; Santacana M; Pallares J; Gatius S; Bergadà L; Maiques O; Matias-Guiu X; Dolcet X
Dis Model Mech; 2013 May; 6(3):710-20. PubMed ID: 23471917
[TBL] [Abstract][Full Text] [Related]
27. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis.
Yu EJ; Hooker E; Johnson DT; Kwak MK; Zou K; Luong R; He Y; Sun Z
PLoS One; 2017; 12(3):e0174357. PubMed ID: 28323888
[TBL] [Abstract][Full Text] [Related]
28. TGFβ signaling limits lineage plasticity in prostate cancer.
Hao Y; Bjerke GA; Pietrzak K; Melhuish TA; Han Y; Turner SD; Frierson HF; Wotton D
PLoS Genet; 2018 May; 14(5):e1007409. PubMed ID: 29782499
[TBL] [Abstract][Full Text] [Related]
29. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.
Thomsen MK; Ambroisine L; Wynn S; Cheah KS; Foster CS; Fisher G; Berney DM; Møller H; Reuter VE; Scardino P; Cuzick J; Ragavan N; Singh PB; Martin FL; Butler CM; Cooper CS; Swain A;
Cancer Res; 2010 Feb; 70(3):979-87. PubMed ID: 20103652
[TBL] [Abstract][Full Text] [Related]
30. Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A₂α via AKT in prostate cancer cells.
Vignarajan S; Xie C; Yao M; Sun Y; Simanainen U; Sved P; Liu T; Dong Q
Oncotarget; 2014 Aug; 5(15):6289-99. PubMed ID: 25026288
[TBL] [Abstract][Full Text] [Related]
31. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice.
Takahara K; Ibuki N; Ghaffari M; Tearle H; Ong CJ; Azuma H; Gleave ME; Pollak M; Cox ME
Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):239-47. PubMed ID: 23689346
[TBL] [Abstract][Full Text] [Related]
32. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
[TBL] [Abstract][Full Text] [Related]
33. KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1α accumulation.
Ci X; Xing C; Zhang B; Zhang Z; Ni JJ; Zhou W; Dong JT
Mol Cancer; 2015 Apr; 14():91. PubMed ID: 25896712
[TBL] [Abstract][Full Text] [Related]
34. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
35. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA
Oncogene; 2012 Jan; 31(3):322-32. PubMed ID: 21685943
[TBL] [Abstract][Full Text] [Related]
36. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
[TBL] [Abstract][Full Text] [Related]
37. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
38. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.
Kwon OJ; Zhang L; Wang J; Su Q; Feng Q; Zhang XH; Mani SA; Paulter R; Creighton CJ; Ittmann MM; Xin L
J Clin Invest; 2016 Jul; 126(7):2626-41. PubMed ID: 27294523
[TBL] [Abstract][Full Text] [Related]
39. In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun.
Riedel M; Berthelsen MF; Cai H; Haldrup J; Borre M; Paludan SR; Hager H; Vendelbo MH; Wagner EF; Bakiri L; Thomsen MK
Oncogene; 2021 Apr; 40(13):2437-2447. PubMed ID: 33674748
[TBL] [Abstract][Full Text] [Related]
40. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]